Outcomes of Surgical Bioprosthetic Aortic Valve Replacement in Patients Y 65 and >65 Years of Age

Abstract Background Implantation of a bioprosthetic valve is a reasonable choice for patients aged >65 years. For middle-aged patients, there is less certainty about whether a mechanical or bioprosthetic valve is best. METHODS The PERIcardial SurGical AOrtic Valve ReplacemeNt (PERIGON) Pivotal Trial is evaluating the safety and efficacy of the Avalus bioprosthesis. We evaluated clinical and echocardiographic outcomes through 5 years of follow-up, stratified by age Y 65 and >65 years. RESULTS Two hundred seventy-one patients (24.2%) were Y 65 years old, and 847 (75.8%) were >65 years old. Most patients in both groups were male (217 [80.1%] vs 623 [73.6%], respectively; p=0.031). Younger patients had a lower STS risk of mortality (1.1±0.9% vs 2.2±1.4%, p Y 65 and >65 years of age. Keywords: age; surgical aortic valve replacement; bioprosthetic pericardial valve.